BioTiChe today announced the publication of a peer-reviewed article titled “Kv3 channel agonist ameliorates the phenotype of a mouse model of amyotrophic lateral sclerosis” in Acta Neuropathologica Communications. The article is available here
The study was conducted through a collaboration led by Prof. Maria Pennuto at the University of Padua, in partnership with Autifony Therapeutics. The research was carried out prior to the formation of BioTiChe by the scientific team that now constitutes the core of the company.
The work demonstrates that Kv3.1 and Kv3.4 channels, traditionally associated with neuronal function, are also expressed in skeletal muscle. Importantly, the study shows that Kv3 expression is reduced in amyotrophic lateral sclerosis (ALS), highlighting a previously underexplored aspect of disease biology. The findings further support Kv3 channel modulation as a promising strategy to influence disease progression in ALS.
This publication aligns with BioTiChe’s mission to advance ion channel focused drug discovery and to translate foundational discoveries into innovative therapies for neurological disorders.
As the first peer-reviewed publication associated with the BioTiChe team, this publication represents a significant achievement and reflects the strength of long-standing collaborations between the company’s scientists and leading academic partners.
Dr. Manuela Marabita, first author of the study and Principal Scientist at BioTiChe, commented: I’m really proud to be the first author of our paper published in Acta Neuropathologica Communications. It’s the result of four years of hard work, and a great collaboration between the University of Padova and our team, working closely together to make something we truly believe in.
